MR-guided focused ultrasound (MRgFUS) and uterine fibroid embolization (UFE) are both non-surgical fibroid treatments that keep the uterus. The only randomized trial to compare them, FIRSTT, found that focused ultrasound was gentler in the first days, with less pain and about half the time off work. Over 3 years, though, UFE gave larger improvements in quality of life and pain, and women who had focused ultrasound were more likely to need another procedure. The trial was small, so these findings are a guide rather than a final verdict.
Here is how the two work, what FIRSTT showed, and who might lean toward each.
How each treatment works
MR-guided focused ultrasound uses many beams of ultrasound energy that meet at a point inside the fibroid and heat it until the tissue is destroyed. You lie inside an MRI scanner, which lets the team aim the beams and watch the temperature in real time. There is no incision and no needle into the fibroid. Treatment works on targeted fibroids, so a specialist must first review your MRI to decide which fibroids can be reached. The FDA approved the first MRgFUS system for fibroids (ExAblate 2000) in October 2004.
UFE works through the blood supply. A thin catheter, entered through an artery at the wrist or groin, carries tiny particles into both uterine arteries. All the fibroids lose their blood flow at once and shrink over the following months. You can read the full overview on our page about uterine fibroid embolization (UFE).
The FIRSTT trial
FIRSTT is the only randomized comparison of these two treatments that we found. It combined a randomized trial with a parallel group of women who chose their treatment, and reported results at the time of treatment (2017) and at 36 months (2019).
An important limitation: the trial reached only 41% of its planned enrollment. In the 3-year analysis, 83 women were treated, 43 with focused ultrasound and 40 with UFE. Small trials can miss real differences or exaggerate them, so the authors' findings should be read with that in mind.
UFE vs focused ultrasound side by side
| Factor (FIRSTT trial) | UFE | Focused ultrasound (MRgFUS) |
|---|---|---|
| Procedure-related time | 139 minutes | 405 minutes; 53% needed 2 treatment days |
| Pain right after treatment (median self-rated score) | 5 | 1 |
| Used opioid pain medicine | 75% | 21% |
| Median days off work | 8 | 4 |
| Median days to return to normal activity | 15 | 10 |
| Adverse events | No significant difference | No significant difference |
| Quality of life and pain at 3 years | Improved more | Improved less |
| Further procedures over 3 years | Lower risk | About 2.8 times the risk (wide range: 1.01 to 7.79) |
| Ovarian reserve marker (AMH) at 24 months | Larger drop | Smaller drop |
Questions about your treatment options? Dr. Fox can help.
Book a ConsultationThis article is part of our Fibroid Treatment Guide.
Short-term: focused ultrasound is easier
In the first days, focused ultrasound clearly asked less of patients. Pain right after treatment was a median score of 1 after MRgFUS, compared with 5 after UFE. Only 21% of MRgFUS patients needed opioid pain medicine, compared with 75% after UFE. Women took a median of 4 days off work after MRgFUS and 8 after UFE, and returned to normal activities after 10 days vs 15. There was no difference in adverse events, and the 2017 report noted no lasting harm or deaths in either group.
The cost of that comfort was time on the table. Focused ultrasound took about 405 minutes of procedure-related time, compared with 139 for UFE, and more than half of MRgFUS patients needed treatment on two separate days.
If you choose UFE, cramping and post-embolization symptoms in the first days are expected and are managed with medication. Our UFE recovery timeline walks through what to expect.
Longer term: UFE held up better
At 36 months, the picture reversed. Women treated with UFE had larger improvements in fibroid quality-of-life scores and in pain. Women treated with focused ultrasound were about 2.8 times as likely to need another procedure. The statistical range around that number was wide, from barely higher to almost 8 times higher, because the trial was small. Younger age and higher ovarian reserve predicted a higher chance of needing more treatment.
A 2025 systematic review of fibroid tissue passing through the vagina after minimally invasive treatments found that focused ultrasound had the highest expulsion rate of the treatments studied. Passing tissue is usually managed without surgery, but it is worth knowing about. For UFE, see our article on passing fibroid tissue after UFE.
Fertility and ovarian reserve
In FIRSTT, AMH, a blood marker of egg supply, fell more after UFE at 24 months than after focused ultrasound. That is a reason for women who may want pregnancy, or who are close to menopause, to discuss the choice carefully. Neither treatment has strong pregnancy data. The FDA's original 2004 approval of the first MRgFUS device was for women who had completed childbearing, and later updates to that labeling were not reviewed for this article. For more on fertility after embolization, read pregnancy after UFE.
Insurance and availability
Coverage is a real difference. Aetna's fibroid policy, last reviewed in April 2026, lists focused ultrasound ablation of fibroids, with or without MRI guidance, as experimental, investigational or unproven, while it considers UFE medically necessary when fibroid symptoms persist. Other insurers set their own rules, so ask your plan in writing before you book. Focused ultrasound also needs a specialized MRI system, so ask any center you are considering how often it performs the treatment.
Which option fits you
When focused ultrasound may be the better choice
- You have a small number of fibroids that a specialist confirms can be treated with MRgFUS
- Fast recovery is your top priority and you accept a higher chance of needing more treatment later
- You want to avoid an artery procedure, for example because of contrast dye allergy or kidney problems (relative reasons to avoid UFE in the CIRSE 2015 guideline)
- Your insurance covers it, or you are prepared to pay yourself
When UFE may be the better choice
- You have many fibroids, or fibroids that are not suitable targets for focused ultrasound
- Lasting symptom relief matters more to you than a few extra days of recovery
- You want the option with more long-term randomized data, including 10-year results against hysterectomy
- Your insurer covers UFE but not focused ultrasound
Neither treatment is right during pregnancy or when cancer is suspected. If pregnancy is a goal, also ask about myomectomy. To compare every option in one place, see our fibroid treatment guide.
Questions to ask before you choose
- Which of my fibroids could be treated with focused ultrasound, and which could not?
- Would I likely need more than one treatment day?
- What is my realistic chance of needing another procedure in the next few years?
- How much time off work should I plan for with each option?
- Will my insurance cover each treatment, and can you check before I book?
- If I may want a pregnancy, how would each option affect that?
Bring your most recent MRI report to these conversations. The answers will often make the choice clearer than any trial average can.
Frequently Asked Questions
Is focused ultrasound better than UFE?
It depends on your priority. In the FIRSTT trial, focused ultrasound had an easier recovery, but UFE gave greater improvement in quality of life and pain at 3 years and a lower chance of repeat treatment.
How long is recovery after focused ultrasound vs UFE?
In FIRSTT, women took a median of 4 days off work after focused ultrasound and 8 days after UFE, and returned to normal activities after 10 vs 15 days.
Does insurance cover MR-guided focused ultrasound for fibroids?
Coverage varies. Aetna's 2026 fibroid policy, for example, lists focused ultrasound ablation as experimental or unproven, while it considers UFE medically necessary for persistent symptoms. Check your own plan.
Can all fibroids be treated with focused ultrasound?
No. A specialist reviews your MRI to decide which fibroids can be safely targeted. UFE treats all fibroids at once through their blood supply.
Which is better for fertility?
Neither has strong pregnancy data. In FIRSTT, an ovarian reserve marker dropped more after UFE. If pregnancy is a goal, also discuss myomectomy.
Keep Reading
- Uterine Fibroid Embolization (UFE) in New York City
- UFE vs Radiofrequency Ablation: Sonata, Acessa and Embolization Compared
- UFE Recovery Day by Day: What to Expect Week by Week
- Pregnancy After UFE: Honest Numbers and What They Mean
- Passing Fibroid Tissue After UFE: Why It Happens and When to Call
- UFE Success Rate: What 1, 2, 5 and 10-Year Studies Show
- Fibroid Treatment Guide: every option, compared
Sources
- Barnard et al., Am J Obstet Gynecol, 2017 — FIRSTT periprocedural outcomes, UAE vs MRgFUS
- Laughlin-Tommaso et al., Am J Obstet Gynecol, 2019 — FIRSTT 36-month results (83 women)
- FDA PMA P040003 — ExAblate 2000 System (Insightec), approved October 2004
- Systematic review of fibroid expulsion after minimally invasive treatment, Eur J Obstet Gynecol Reprod Biol, 2025
- van Overhagen and Reekers, Cardiovasc Intervent Radiol, 2015 — CIRSE standards of practice for UAE
- de Bruijn et al., Am J Obstet Gynecol, 2016 — EMMY trial 10-year results
- Aetna Clinical Policy Bulletin 0304 — Fibroid Treatment (last review April 2026)
Medically reviewed by David Fox, MD, FACS, RPVI. This article is general information, not a substitute for a medical evaluation.
Living with heavy periods, pelvic pressure or other fibroid symptoms? Schedule a consultation with Dr. David Fox at Fox Vein & Vascular in Manhattan to find out whether uterine fibroid embolization is right for you. Call (212) 362-3470 or request a UFE consultation online.
